09:17 AM EDT, 04/29/2025 (MT Newswires) -- AbbVie ( ABBV ) said Tuesday that the US Food and Drug Administration has approved its Rinvoq medication for the treatment of adults with giant cell arteritis.

The FDA decision follows the European Commission also recently granting marketing authorization for Rinvoq within its jurisdiction.

During phase 3 testing, Rinvoq, together with a steroid taper regimen, demonstrated sustained remission in 46.4% of patients with giant cell arteritis between week 12 to week 52 compared to 29% of the patients treated with a placebo and the steroid taper, the company said.

AbbVie ( ABBV ) shares were 0.1% higher during Tuesday's pre-market.